Growth Hormone Stimulation Test: Lab "Normal" vs Functional Optimal

What the Growth Hormone Stimulation Test Actually Measures

A GH stimulation test does not measure resting GH. Basal GH is pulsatile and can be undetectable even in healthy adults at any given moment. The test instead applies a defined physiological or pharmacological stress, then samples serum GH at 0, 30, 60, 90, and 120 minutes to capture peak output. That peak reflects the pituitary's secretory reserve.

The stimulus matters enormously. Insulin-induced hypoglycemia (the insulin tolerance test, ITT) remains the reference standard because it reliably activates hypothalamic GH-releasing hormone pathways. Macimorelin, an oral ghrelin mimetic approved by the FDA in 2017, offers a safer alternative with equivalent diagnostic accuracy in the MACRILEN key trial (N=157, sensitivity 87%, specificity 96%) [1].

Why Random GH Is Clinically Useless

A single random GH draw has no diagnostic value. GH pulses occur 6 to 12 times per 24 hours, with nadir values indistinguishable from deficiency states. The Endocrine Society's 2011 Clinical Practice Guideline states explicitly: "A single random GH measurement cannot be used to diagnose or exclude GH deficiency" [2]. Stimulation protocols standardize the conditions so peak values become comparable across patients and over time.

Assay Standardization Problems

GH immunoassays are not interchangeable. A 2018 study in the Journal of Clinical Endocrinology and Metabolism (N=81 samples across 8 platforms) found up to 2.1-fold variation in GH concentrations from the same sample [3]. Most modern assays are calibrated to the WHO IS 98/574 recombinant standard, but older polyclonal antibody assays yield systematically higher values. This means a result of 6.0 ng/mL on one platform might read as 3.2 ng/mL on another. Any comparison of GH stim test results across institutions requires assay harmonization data.

Laboratory "Normal" Ranges: How They Are Set

Reference ranges for GH stimulation tests are derived from population studies of healthy volunteers undergoing the same stimulus. They are statistical constructs, typically the central 95th percentile of that population's peak GH response.

Adult vs Pediatric Cutoffs

In children, most laboratories define a normal peak GH as above 10 ng/mL. The Endocrine Society pediatric guideline uses a 10 ng/mL threshold for most stimuli, though some European centers use 6.1 ng/mL with modern recombinant-standard assays [4]. In adults, the diagnostic threshold is lower because GH secretion physiologically declines after age 30 at roughly 14% per decade [5].

The 2019 Endocrine Society update recommends the following adult cutoffs by stimulus [2]:

| Stimulus | GH deficiency cutoff (ng/mL) | |---|---| | Insulin tolerance test (ITT) | <5.1 | | Glucagon stimulation test | <3.0 | | Macimorelin (Macrilen) | <2.8 | | Arginine + GHRH | <4.1 (BMI-adjusted) |

BMI Adjusts the Cutoff

Obesity suppresses GH secretion independently of pituitary function. For the arginine plus GHRH test, the GHRH-arginine cutoff is BMI-stratified: below 4.1 ng/mL for BMI <25, below 3.0 ng/mL for BMI 25 to 30, and below 1.0 ng/mL for BMI above 30 [2]. Applying a single flat cutoff in an obese patient dramatically over-diagnoses GHD. This adjustment is one area where many general practitioners ordering the test go wrong.

What Counts as "Normal"

A peak GH at or above the stimulus-specific cutoff is reported as "normal" by the laboratory. This binary answer satisfies diagnostic coding and insurance requirements. It does not tell the ordering physician where the patient sits relative to youthful secretory capacity or whether symptoms correlate with a suboptimal response.

Functional Optimal: A Different Question

"Normal" asks: does this patient have a diagnosable disease? "Functional optimal" asks: at what GH secretory output do patients feel and function best, and does this patient reach that level?

These are genuinely different questions. A patient with a peak GH of 5.5 ng/mL clears the ITT diagnostic threshold for normality but may still report fatigue, reduced lean mass, increased visceral adiposity, and impaired bone density that correlate with suboptimal GH axis activity.

The Evidence for Higher Functional Thresholds

Data from the KIMS (Pfizer International Metabolic Database) registry, which tracked over 13,000 GH-deficient adults receiving rhGH replacement, showed that quality-of-life scores (QoL-AGHDA) and body composition continued to improve as IGF-1 Z-scores rose from minus 1.0 toward zero [6]. Patients with "normal" but low-normal IGF-1 (Z-score minus 1.5 to minus 1.0) carried measurably worse metabolic profiles than age-matched controls.

A 2016 meta-analysis in Clinical Endocrinology (24 RCTs, N=1,373) found that rhGH replacement in adults with confirmed GHD reduced total cholesterol by 0.29 mmol/L and LDL by 0.24 mmol/L, with the largest effects in patients with pre-treatment IGF-1 Z-scores below minus 1.0 [7]. This implies a clinically meaningful range between the diagnostic cutoff and the population mean.

Where Experts Place the Functional Optimal

Most endocrinologists practicing in GH replacement clinics target a post-treatment IGF-1 Z-score between 0 and plus 1.0 (age and sex normalized), not merely above the deficiency threshold. On the stimulation side, a peak GH above 11 ng/mL on ITT is widely cited in clinical practice as consistent with adequate pituitary reserve, though no single RCT has formally validated this number as a threshold for withholding treatment.

The HealthRX clinical team applies a three-tier framework when reviewing stim test results:

• Tier 1 (Overt deficiency): Peak GH below the stimulus-specific Endocrine Society cutoff. Diagnosis confirmed; rhGH initiation appropriate pending clinical assessment.
• Tier 2 (Gray zone): Peak GH at 100 to 200% of the diagnostic cutoff, with IGF-1 Z-score below minus 1.0, low lean mass index, elevated visceral adipose on DEXA, and concordant symptoms. Warrants a trial of low-dose rhGH or a repeat test with a second stimulus.
• Tier 3 (Functional normal): Peak GH above 11 ng/mL on ITT (or stimulus-equivalent), IGF-1 Z-score at or above minus 0.5. Symptoms unlikely to stem from the GH axis; workup redirected.

How the Test Is Performed: Step-by-Step

Understanding the protocol helps patients and clinicians interpret whether the result is technically valid.

Patient Preparation

The patient fasts overnight (at least 8 hours). Hypothyroidism must be treated before testing because untreated hypothyroidism blunts GH response by up to 40% [2]. Exogenous glucocorticoids should be held for at least 12 hours if clinically safe, as they suppress GH secretion. Female patients on estrogen therapy may need higher cutoffs because oral estrogens reduce IGF-1 generation without changing pituitary GH output [8].

The Insulin Tolerance Test Protocol

An IV line is placed. Regular insulin is administered at 0.1 to 0.15 units/kg IV at time zero. A blood glucose below 40 mg/dL (2.2 mmol/L) confirms adequate hypoglycemia and validates the stimulus. GH samples are drawn at 0, 30, 45, 60, and 90 minutes. The ITT is contraindicated in patients with a history of seizures, ischemic heart disease, or unexplained syncope [2]. A physician or trained nurse must remain present throughout.

The Macimorelin Test Protocol

Macimorelin (0.5 mg/kg) is dissolved in water and swallowed after an 8-hour fast. GH is sampled at 30, 45, 60, and 90 minutes post-ingestion. The FDA approval was based on a peak GH below 2.8 ng/mL as the deficiency cutoff [1]. Macimorelin does not require an IV line or supervised hypoglycemia, making it safer for outpatient settings. Strong CYP3A4 inducers (rifampin, carbamazepine) reduce macimorelin exposure and may produce false-positive deficiency results [9].

The Glucagon Stimulation Test

Glucagon (1 mg IM, or 1.5 mg for patients above 90 kg) is given at time zero. GH sampling occurs at 0, 90, 120, 150, 180, and 210 minutes. Peak GH below 3.0 ng/mL confirms GHD. The glucagon test is preferred when ITT is contraindicated and macimorelin is unavailable. A 2014 study in JCEM (N=51) showed 96% sensitivity and 100% specificity vs ITT at this cutoff [10].

What a High GH Stimulation Test Result Means

An unusually high peak GH response on stimulation testing is not simply "very good pituitary reserve." In the context of a workup for suspected acromegaly, a paradoxical GH rise after oral glucose loading (not a stimulation test per se, but a related dynamic protocol) confirms autonomous GH excess. On a standard stimulation test, a peak GH above 20 ng/mL in an adult raises no specific concern in isolation, but should be interpreted alongside IGF-1, clinical signs, and pituitary imaging.

Acromegaly Uses a Suppression Test, Not a Stimulation Test

Acromegaly is diagnosed by failure of GH suppression below 1 ng/mL (older assays) or below 0.4 ng/mL (modern assays) after a 75-gram oral glucose load [11]. The Endocrine Society 2014 acromegaly guideline specifies this oral glucose tolerance test (OGTT) as the confirmatory test, not a stimulation protocol [11]. Ordering a stimulation test to diagnose acromegaly is the wrong test for the wrong question.

What a Low GH Stimulation Test Means

A subnormal peak GH confirms impaired pituitary secretory reserve. The clinical significance depends on whether deficiency is isolated or part of combined hypopituitarism.

Isolated Adult-Onset GH Deficiency

Isolated adult GH deficiency (AGHD) most often follows pituitary surgery, cranial irradiation, or a pituitary adenoma [2]. The KIMS registry data show that AGHD patients have a cardiovascular mortality rate approximately 1.4 times that of age-matched controls, driven largely by adverse lipid profiles and increased visceral fat mass [6]. RhGH replacement at starting doses of 0.1 to 0.3 mg/day SC, titrated to normalize IGF-1, reduces these surrogates significantly.

Childhood-Onset GH Deficiency Transitioning to Adult Care

Adolescents diagnosed with GHD during childhood require re-testing after growth plates close. Approximately 25 to 30% of children who met pediatric GHD criteria will have normal GH secretion as adults [4]. Retesting uses an adult protocol and adult cutoffs. The Endocrine Society recommends a washout period of at least 1 month off rhGH before re-testing [2].

Functional GH Deficiency from Obesity

A peak GH below 3.0 ng/mL in a patient with BMI above 35 may reflect adipose-driven somatostatin tone rather than true pituitary failure. Weight loss of 10% body weight has been shown to increase mean 24-hour GH secretion by 2 to 3 fold in obese subjects [12]. Clinicians should apply BMI-adjusted cutoffs and, where possible, obtain a GHRH-arginine test with the appropriate BMI-stratified threshold before attributing a low result to pituitary disease.

How to Raise a Low GH Stimulation Test Response

The only intervention that reliably raises a pathologically low peak GH on re-testing is treating the underlying pituitary disease or removing reversible suppressors.

Reversible Causes to Address First

• Untreated hypothyroidism: normalize free T4 before repeat testing [2].
• Glucocorticoid excess: treat Cushing's disease or taper exogenous steroids.
• Obesity: document whether 10% weight loss improves spontaneous GH output before initiating rhGH [12].
• Oral estrogen: switch to transdermal estradiol if possible, as oral estrogen reduces IGF-1 generation and may confound result interpretation [8].

Pharmacological GH Replacement

When the diagnosis is confirmed, recombinant human GH (somatropin) is initiated at 0.1 to 0.3 mg/day SC and titrated every 4 to 8 weeks based on IGF-1, symptoms, and tolerability. The 2019 Endocrine Society guideline targets an IGF-1 Z-score of 0 to plus 1.0 [2]. Doses are generally lower in older patients and those with diabetes risk. The NICE Technology Appraisal TA64 (UK) endorses rhGH in adults with confirmed GHD and QoL-AGHDA scores above 11 [13].

Peptide Secretagogues (Off-Label Context)

Ghrelin mimetics and GHRH analogs such as tesamorelin, sermorelin, and CJC-1295 stimulate endogenous GH secretion rather than replacing it directly. Tesamorelin (Egrifta) carries FDA approval for HIV-associated lipodystrophy at 2 mg/day SC and reduced trunk fat by 18% vs placebo (P<0.001) in the LIPO-010 trial (N=412) [14]. Use of these agents to raise a borderline stimulation test response in non-HIV adults is off-label and not endorsed by current Endocrine Society guidelines.

How to Interpret Results in Context: IGF-1 as the Companion Biomarker

A GH stimulation test result should never be read in isolation. IGF-1 (insulin-like growth factor 1) is synthesized in the liver in response to GH and provides an integrated index of GH bioactivity over 24 to 72 hours.

IGF-1 Z-Scores, Not Raw Values

IGF-1 reference ranges shift dramatically with age and sex. A raw value of 120 ng/mL is deficient in a 25-year-old male (expected 200 to 450 ng/mL) but normal in a 70-year-old. Age and sex-normalized Z-scores are the only valid comparison. An IGF-1 Z-score below minus 2.0 in the presence of pituitary disease is sufficient to diagnose severe GHD without stimulation testing in adults who have three or more other pituitary hormone deficiencies, per Endocrine Society guidance [2].

When Stimulation Testing Can Be Skipped

Patients with a history of hypothalamic-pituitary surgery or irradiation, two or more additional confirmed pituitary hormone deficiencies, and an IGF-1 Z-score below minus 2.0 meet diagnostic criteria for severe AGHD without a formal stimulation test [2]. This exception reduces patient burden and avoids the risks of ITT-induced hypoglycemia in a frail post-operative population.

IGFBP-3 as a Pediatric Adjunct

In children younger than 5, IGF-1 levels are low even in healthy subjects, limiting diagnostic discrimination. Insulin-like growth factor binding protein 3 (IGFBP-3) has better sensitivity in this age group. A serum IGFBP-3 below minus 2.0 SD for age supports GHD diagnosis in young children where stimulation test interpretation is uncertain [4].

Special Populations: What Changes

Women

Estrogen raises GH secretion via increased hypothalamic GHRH output. Women of reproductive age mount higher peak GH responses than age-matched men on the same stimulus. Oral contraceptive pills containing ethinyl estradiol further raise GH peaks, potentially masking mild GHD. Postmenopausal women not on HRT tend to have lower GH peaks than premenopausal controls [8]. Clinicians should document menstrual status and current estrogen formulation before ordering the test.

Older Adults

GH secretion declines with age. A 70-year-old without pituitary disease may produce a peak GH of only 3 to 5 ng/mL on ITT, falling below the cutoff derived from younger populations. Age-adjusted interpretation is not yet formally standardized across guidelines, but the AACE/ACE 2019 position statement notes that elderly patients require clinical judgment layered onto biochemical cutoffs [15].

Athletes and High-Volume Exercisers

Trained athletes have augmented GH secretory dynamics at baseline. They may show falsely elevated stim test peaks that obscure mild pituitary pathology. Conversely, relative energy deficiency in sport (RED-S) can suppress the GH-IGF-1 axis through nutritional mechanisms without true pituitary disease [4].